Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension.

Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, Heinrich D, Molven A, Lønning PE, Akslen LA, Straume O.

PLoS One. 2012;7(6):e38364. doi: 10.1371/journal.pone.0038364. Epub 2012 Jun 15.


Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.

Ferrucci PF, Minchella I, Mosconi M, Gandini S, Verrecchia F, Cocorocchio E, Passoni C, Pari C, Testori A, Coco P, Munzone E.

Melanoma Res. 2015 Jun;25(3):239-45. doi: 10.1097/CMR.0000000000000146.


Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.

Mahalingam D, Malik L, Beeram M, Rodon J, Sankhala K, Mita A, Benjamin D, Ketchum N, Michalek J, Tolcher A, Wright J, Sarantopoulos J.

Cancer Chemother Pharmacol. 2014 Jul;74(1):77-84. doi: 10.1007/s00280-014-2479-8. Epub 2014 May 10.


Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

Perez DG, Suman VJ, Fitch TR, Amatruda T 3rd, Morton RF, Jilani SZ, Constantinou CL, Egner JR, Kottschade LA, Markovic SN.

Cancer. 2009 Jan 1;115(1):119-27. doi: 10.1002/cncr.23987.


A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.

Harshman LC, Barbeau S, McMillian A, Srinivas S.

Clin Genitourin Cancer. 2013 Jun;11(2):100-6. doi: 10.1016/j.clgc.2012.12.002. Epub 2013 Jan 24.


Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.

Gampenrieder SP, Romeder F, Muß C, Pircher M, Ressler S, Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, Greil R.

Anticancer Res. 2014 Jan;34(1):227-33.


Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.

Gray MR, Martin del Campo S, Zhang X, Zhang H, Souza FF, Carson WE 3rd, Smith AD.

Radiology. 2014 Feb;270(2):425-34. doi: 10.1148/radiol.13130776. Epub 2013 Oct 28.


VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.

Martin LK, Li X, Kleiber B, Ellison EC, Bloomston M, Zalupski M, Bekaii-Saab TS.

Ann Oncol. 2012 Nov;23(11):2812-20. doi: 10.1093/annonc/mds134. Epub 2012 Jul 5.


Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.

Zhong J, Ali AN, Voloschin AD, Liu Y, Curran WJ Jr, Crocker IR, Shu HK.

Cancer. 2015 May 1;121(9):1456-62. doi: 10.1002/cncr.29234. Epub 2014 Dec 29.


A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma.

Vihinen PP, Hernberg M, Vuoristo MS, Tyynelä K, Laukka M, Lundin J, Ivaska J, Pyrhönen S.

Melanoma Res. 2010 Aug;20(4):318-25. doi: 10.1097/CMR.0b013e3283390365.


The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.

Budai B, Nagy T, Láng I, Hitre E.

Angiogenesis. 2013 Jan;16(1):113-21. doi: 10.1007/s10456-012-9303-z. Epub 2012 Sep 6.


A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

Johnsson A, Hagman H, Frödin JE, Berglund A, Keldsen N, Fernebro E, Sundberg J, De Pont Christensen R, Garm Spindler KL, Bergström D, Jakobsen A.

Ann Oncol. 2013 Sep;24(9):2335-41. doi: 10.1093/annonc/mdt236. Epub 2013 Jun 19.


High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.

Hainsworth JD, Shipley DL, Reeves J Jr, Arrowsmith ER, Barnes EK, Waterhouse DM.

Clin Genitourin Cancer. 2013 Sep;11(3):283-289.e1. doi: 10.1016/j.clgc.2013.04.014. Epub 2013 May 15.


A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, Wu H, Lesinski GB, Kendra K, Chen HX, Walker MJ, Carson WE 3rd.

Ann Surg Oncol. 2007 Aug;14(8):2367-76. Epub 2007 May 30.


BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O'Day SJ.

J Clin Oncol. 2012 Jan 1;30(1):34-41. doi: 10.1200/JCO.2011.34.6270. Epub 2011 Nov 28.


[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].

Lin L, Xu JM, Wang Y, Ge FJ, Liu LJ, Zhao CH, Li SS, Liu JZ, Li ZQ.

Zhonghua Zhong Liu Za Zhi. 2010 Oct;32(10):786-90. Chinese.


Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.

Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, Yu SY, Ba Y, Liang J, Wang D, Qin SK, Wang JJ, He J, Qi C, Xu RH.

Chin J Cancer. 2011 Oct;30(10):682-9. doi: 10.5732/cjc.011.10188.


Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.

Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi E, Gemma D, Gamucci T, Grande R, Pavese I, Franco D, Ruggeri EM.

Invest New Drugs. 2013 Aug;31(4):1035-43. doi: 10.1007/s10637-013-9936-9. Epub 2013 Feb 17.


A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.

Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, Kefauver C, Wei L, Walker MJ, Chen HX, Kendra K, Carson WE 3rd.

J Immunother. 2011 Jul-Aug;34(6):509-15. doi: 10.1097/CJI.0b013e31821dcefd.


N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.

Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA.

Ann Oncol. 2013 Oct;24(10):2548-54. doi: 10.1093/annonc/mdt213. Epub 2013 Jun 24.

Supplemental Content

Support Center